Logo

Eurofins Genomics Oligonucleotide Synthesizer Platform

Feb 23, 2017

Eurofins Genomics has launched its new DNA synthesizer platform. The platform synthesizes EXTREmer oligonucleotides. The oligonucleotides are up to 200 bases long with a coupling efficiency of 99.5 percent or greater. The EXTREmers allow for the construction of genes with segments of low sequence variability that would be difficult to sequence with shorter oligonucleotides, the company said. They can also be used as a template for in vitro transcription of RNA molecules.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.